SAN JOSE, CA November 24, 2015
SoundCure, Inc. today announced receipt of a Medical Device License from Health Canada, a department of the Canadian government that is engaged in public health matters, for the SoundCure® Serenade® Tinnitus Treatment System. The medical license enables the SoundCure Serenade to be available in Canada.
SoundCure also received a Notice of Allowance from the Canadian Patent Office for a key device and method patent titled, "Devices and Methods for Suppression of Tinnitus", which relates to SoundCure's custom S-Tone sound therapy available on the Serenade device. This enables SoundCure to partner with hearing healthcare providers in Canada to benefit those suffering with tinnitus.
Commonly known as "ringing in the ears", tinnitus is a potentially debilitating condition affecting an estimated one in ten adults. Serenade, which is currently commercially available in the US and the UK, is a handheld medical device that delivers customized sound therapy, one of the most accepted treatment approaches for tinnitus. After the Serenade device is programmed by a hearing healthcare provider, the patient uses it to play proprietary treatment tones known as S-Tones® when relief is needed.
S-Tones are designed to be listened to very softly, at a volume lower than one's tinnitus and lower than traditional maskers, in order to minimize the patient's sound burden and provide long-term relief through the process of habituation. For those whose tinnitus seems particularly loud and bothersome, correcting the over-perception of tinnitus and increasing the periods of time where the patient doesn't notice the tinnitus at all through habituation, can bring substantial relief.
Bill Perry, Chief Executive Officer of SoundCure, said, "Receiving the Canadian Medical License from Health Canada and the patent allowance from the Canadian Patent Office are important achievements for SoundCure. In addition to having two US FDA-cleared products, CE Mark, ISO certification, and patents in Europe, the US and Asia, we are thrilled to introduce our products in Canada. We look forward to providing relief to patients in partnership with hearing healthcare providers in Canada."
SoundCure is a subsidiary of Boston-based Allied Minds (LSE: ALM). More information about the company can be found at www.soundcure.com.
About SoundCure, Inc. SoundCure, Inc. is a privately held medical device company whose mission is to revolutionize the treatment of tinnitus and provide relief to the millions of people suffering its effects. SoundCure is an Allied Minds company.
About Allied Minds Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risk and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.